Sandoz Group AG (SWX:SDZ)
63.74
-0.34 (-0.53%)
Apr 2, 2026, 11:14 AM CET
Sandoz Group AG Revenue
In the year 2025, Sandoz Group AG had annual revenue of $11.16B USD with 7.44% growth. Sandoz Group AG had revenue of $5.89B in the half year ending December 31, 2025, with 16.70% growth.
Revenue
$11.16B
Revenue Growth
+7.44%
P/S Ratio
3.13
Revenue / Employee
$499.06K
Employees
22,356
Market Cap
27.73B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.16B | 773.00M | 7.44% |
| Dec 31, 2024 | 10.38B | 405.00M | 4.06% |
| Dec 31, 2023 | 9.98B | 673.00M | 7.23% |
| Dec 31, 2022 | 9.31B | -372.00M | -3.84% |
| Dec 31, 2021 | 9.68B | 20.00M | 0.21% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.36B |
| Novartis AG | 44.94B |
| Alcon | 8.25B |
| Lonza Group AG | 6.53B |
| Galderma Group AG | 4.16B |
| Galenica AG | 4.15B |
| Sonova Holding AG | 3.85B |
| Straumann Holding AG | 2.61B |
Sandoz Group AG News
- 15 days ago - Strides Pharma shares over 3% after acquiring generic brands from Sandoz for US$ 12 million - Business Upturn
- 15 days ago - Strides Pharma Science acquires generic brands from Sandoz for US$ 12 million - Business Upturn
- 4 weeks ago - Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's - Nasdaq
- 5 weeks ago - Sandoz Shares Jump on Improved Guidance - WSJ
- 4 months ago - Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz - Accesswire
- 5 months ago - Sandoz CEO expects Ozempic biosimilars to enter Canadian market in Q1, Q2 - Reuters
- 5 months ago - EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A - PRNewsWire
- 5 months ago - Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities - Accesswire